# Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

> **NCT00420212** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 1234 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** BG00012
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00420212
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 1234 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420212, "Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00420212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*